Equities

Phibro Animal Health Corp

Phibro Animal Health Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.93
  • Today's Change-0.13 / -1.00%
  • Shares traded158.76k
  • 1 Year change-11.92%
  • Beta0.7461
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 770 product lines in over 80 countries to approximately 4,000 customers. The Company has three segments. Animal Health segment develops, manufactures and markets about 270 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. Mineral Nutrition segment manufactures and markets approximately 420 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.

  • Revenue in USD (TTM)982.01m
  • Net income in USD14.80m
  • Incorporated2014
  • Employees1.92k
  • Location
    Phibro Animal Health Corp300 Frank W. Burr Blvd.Suite 21, 65 Challenger RoadTEANECK 07666United StatesUSA
  • Phone+1 (201) 329-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pahc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lexeo Therapeutics Inc0.00-66.39m503.11m58.00--3.59-----2.69-2.690.004.26------0.00--------------------0.0153---100.00---12.01------
Replimune Group Inc0.00-209.96m506.45m284.00--1.20-----3.16-3.160.006.870.00----0.00-34.66-26.12-36.63-27.31------------0.1436-------47.65--75.59--
PetIQ Inc1.10bn2.13m513.28m1.93k284.182.3210.450.46580.06140.061435.697.521.315.638.46570,079.100.301-4.320.3777-5.2322.9420.050.2304-3.661.431.740.6671--19.5815.83104.42--4.96--
Revance Therapeutics Inc234.04m-323.99m514.83m534.00------2.20-3.81-3.812.77-1.720.44142.3312.00---61.11-55.55-72.36-63.2068.23---138.43-304.963.29-36.361.54--76.55128.849.10---0.3022--
Lyell Immunopharma Inc130.00k-234.63m518.36m224.00--0.791--3,987.36-0.9353-0.93530.00052.580.0002----580.36-27.81---29.04-------180,486.20------0.00---99.85---28.13------
Voyager Therapeutics Inc250.01m132.33m519.11m162.003.231.783.802.082.962.965.565.370.9792--5.971,543,259.0051.830.637870.850.8203----52.931.30----0.000.00511.16101.01385.14---5.43--
Cibus Inc1.82m-267.63m525.35m183.00--1.53--289.13-22.63-22.630.176914.270.0064----9,928.96-119.13-86.28-135.32-96.452.31---18,582.22-792.07---3.700.0049--1,057.3350.41-1,484.44--18.53--
Phibro Animal Health Corp982.01m14.80m528.98m1.92k35.741.9510.660.53870.36540.365424.246.691.022.376.49511,465.601.535.461.876.8330.4331.411.515.111.602.500.636942.993.783.59-33.69-13.5622.803.71
Tevogen Bio Holdings Inc0.00-62.57m537.07m-----------0.4043-0.40430.00-0.5867---------------------------8.7442.99-------41.32------
Solid Biosciences Inc0.00-96.02m538.04m88.00--2.30-----4.84-4.840.006.200.00----0.00-45.16-49.99-49.47-56.25-------2,117.05----0.0133---100.00---11.67---27.90--
Lexicon Pharmaceuticals Inc1.21m-177.12m539.26m285.00--5.76--447.52-0.7975-0.79750.00550.38020.0057--2.324,228.07-83.60-24.41-96.00-29.0190.9598.49-14,698.67-84.925.58-13.110.5166--766.19-54.71-73.74--37.68--
Mersana Therapeutics Inc36.86m-171.67m544.65m123.00--14.69--14.78-1.50-1.500.31750.30570.1315--2.46299,634.20-61.27-61.68-84.73-81.35-----465.80-622.19----0.408--38.6528.3215.94--9.61--
IGM Biosciences Inc2.13m-246.42m544.95m224.00--2.68--255.85-4.81-4.810.04073.460.0046----9,508.93-52.60-44.66-58.00-48.20-----11,568.83-23,668.96----0.00--99.25---11.45--73.48--
Biomea Fusion Inc0.00-107.69m548.44m103.00--2.75-----3.34-3.340.005.590.00----0.00-58.19---63.10--------------0.00-------96.86------
C4 Therapeutics Inc20.76m-132.49m552.24m145.00--1.98--26.61-2.67-2.670.41814.070.0514--3.13143,144.80-32.82-25.91-36.80-29.45-----638.34-292.35----0.00---33.251.40-3.37---8.68--
Data as of Mar 28 2024. Currency figures normalised to Phibro Animal Health Corp's reporting currency: US Dollar USD

Institutional shareholders

64.60%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20233.30m16.21%
Brandes Investment Partners LPas of 31 Dec 20232.13m10.47%
Pzena Investment Management LLCas of 31 Dec 20231.99m9.78%
The Vanguard Group, Inc.as of 31 Dec 20231.76m8.67%
SSgA Funds Management, Inc.as of 31 Dec 2023947.22k4.66%
Dimensional Fund Advisors LPas of 31 Dec 2023777.10k3.82%
Millennium Management LLCas of 31 Dec 2023609.61k3.00%
Renaissance Technologies LLCas of 31 Dec 2023574.60k2.83%
Hotchkis & Wiley Capital Management LLCas of 31 Dec 2023540.93k2.66%
Acadian Asset Management LLCas of 31 Dec 2023508.43k2.50%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.